Rhythm Pharmaceuticals, Inc.
RYTM
$103.94
$2.552.52%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 51.30M | 48.50M | 32.70M | 41.83M | 33.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 51.30M | 48.50M | 32.70M | 41.83M | 33.25M |
| Cost of Revenue | 5.50M | 5.54M | 3.65M | 3.79M | 3.83M |
| Gross Profit | 45.80M | 42.96M | 29.06M | 38.04M | 29.42M |
| SG&A Expenses | 52.43M | 45.95M | 39.09M | 38.13M | 35.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 103.95M | 93.80M | 79.71M | 83.09M | 77.14M |
| Operating Income | -52.65M | -45.30M | -47.00M | -41.26M | -43.89M |
| Income Before Tax | -52.79M | -46.30M | -49.42M | -43.38M | -43.99M |
| Income Tax Expenses | 111.00K | 337.00K | 80.00K | -90.00K | -344.00K |
| Earnings from Continuing Operations | -52.90M | -46.63M | -49.50M | -43.29M | -43.64M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.90M | -46.63M | -49.50M | -43.29M | -43.64M |
| EBIT | -52.65M | -45.30M | -47.00M | -41.26M | -43.89M |
| EBITDA | -52.35M | -44.92M | -46.62M | -40.87M | -43.50M |
| EPS Basic | -0.82 | -0.75 | -0.81 | -0.72 | -0.73 |
| Normalized Basic EPS | -0.50 | -0.45 | -0.49 | -0.44 | -0.45 |
| EPS Diluted | -0.82 | -0.75 | -0.81 | -0.72 | -0.73 |
| Normalized Diluted EPS | -0.50 | -0.45 | -0.49 | -0.44 | -0.45 |
| Average Basic Shares Outstanding | 66.26M | 63.68M | 63.06M | 61.60M | 61.22M |
| Average Diluted Shares Outstanding | 66.26M | 63.68M | 63.06M | 61.60M | 61.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |